Homozygous familial hypercholesterolemia (HoFH) is a rare and severe genetic disorder characterized by abnormally high levels of low-density lipoproteins (LDL) in the blood, leading to early development of atherosclerosis and cardiovascular disease. This condition is caused by inherited mutations in the genes responsible for cholesterol metabolism, making patients extremely vulnerable to the development of cardiovascular complications. Unlike the heterozygous form of hypercholesterolemia, with HoFH the patient will inherit two defective alleles (one from each parent), which leads to a more pronounced clinical picture with significant lipid metabolism disorders. It is important to note that in the absence of adequate treatment, LDL levels can reach threatening values, which requires an active and comprehensive approach to clinical monitoring and therapy.
History of the disease and interesting historical facts
Homozygous familial hypercholesterolemia was first described in the 1930s, when they noticed a connection between high cholesterol and a predisposition to premature cardiovascular disease. The development of ideas about this pathology was significantly influenced by studies conducted in the 1970s and 1980s, which first proposed the concept of the genetic nature of the disease and its connection with mutations in the genes responsible for lipid metabolism. One of the landmark moments was the discovery in 1986 of the gene responsible for LDL receptors, which allowed significant progress in understanding the molecular mechanisms of the disease. Since then, research has been ongoing to study the genetic aspects, clinical features and effective treatment methods for HoFH.
Epidemiology
The prevalence of homozygous familial hypercholesterolemia is estimated to be between 1 in 160,000 and 1 in 300,000 live births. These figures may vary by geographic region and ethnicity. For example, in some areas of Northern Europe the incidence is higher, due to inheritance patterns in populations. HoFH is diagnosed much less frequently in clinical practice than heterozygous forms of hypercholesterolemia, making it difficult to collect statistics. However, data show that with proper diagnosis the incidence rate can be corrected and patients can receive timely therapy.
Genetic predisposition to this disease
Homozygous familial hypercholesterolemia is associated primarily with mutations in genes involved in cholesterol metabolism, primarily the LDLR gene, which codes for the LDL receptor. Mutations can be varied and can manifest as either spot changes or large deletions or insertions. Other genes involved include APOB and PCSK9, which also have a significant impact on cholesterol levels in the body. These mutations begin to manifest early in life, often in childhood, so this type of hypercholesterolemia requires early diagnosis and genetic testing.
Risk factors for the development of this disease
Risk factors that contribute to the development of homozygous familial hypercholesterolemia include:
- Heredity - the presence of cases of the disease in the family.
- Sometimes lifestyle choices that include low physical activity and poor diet can make symptoms worse.
- Age - often the pathology manifests itself in childhood or adolescence.
- Co-morbidities such as diabetes may also negatively impact lipid profiles.
These factors can influence the severity of clinical manifestations and the rate of disease progression.
Diagnosis of this disease
Diagnosis of homozygous familial hypercholesterolemia requires a comprehensive approach that takes into account both clinical manifestations and the results of laboratory and radiological studies.
- The main symptoms include a marked increase in cholesterol levels, which can reach 600–1000 mg/dL, as well as the presence of xanthomatoses and xanthomas in the elbows and knees.
- Laboratory tests: blood lipid analysis, genetic testing for mutations in the relevant genes.
- Radiological examinations often include ultrasound diagnostics to detect atherosclerotic changes in the vessels.
- Differential diagnosis is important to exclude other diseases, such as heterozygous hypercholesterolemia and other lipid metabolism disorders.
These measures allow not only to confirm the diagnosis, but also to assess the severity of the patient’s condition.
Treatment
Treatment of homozygous familial hypercholesterolemia should be comprehensive and usually includes:
- General recommendations include lifestyle changes, including dietary interventions, limiting saturated fats and increasing physical activity.
- Pharmacological treatment may include statins, PCSK9 inhibitors, rubber. These drugs help reduce LDL levels in the blood.
- Surgical treatment, such as staged plasmapheresis or liver transplantation, may be considered in severe cases where conservative methods are ineffective.
- Other treatments may include experimental drugs or participation in clinical trials.
Effective medical care requires constant monitoring and an individual approach to each patient.
List of medications used to treat this disease
- Stanols (stanines) - Atorvastatin, Simvastatin.
- PCSK9 inhibitors - Evolocumab, Alirocumab.
- Probucol.
- Fibrates - Fenofibrate, Bezafibrate.
- Experimental drugs - such as Avaloscan injections.
This list is not exhaustive and may be adjusted depending on new research and clinical practice.
Disease monitoring
Monitoring the condition of a patient with HoFH includes regular control measures:
- Monitoring the levels of cholesterol and other lipids in the blood.
- Evaluation of treatment effectiveness with periodic adjustment of therapy.
- Scheduling regular check-ups to detect possible complications such as coronary heart disease or stroke early.
The prognosis for patients receiving adequate treatment is improving, but the disease carries a risk of serious complications such as heart failure or acute coronary event.
Age-related features of the disease
Homozygous familial hypercholesterolemia may present differently depending on the age group of patients:
- In children, symptoms may manifest as obvious xanthomas and severe lipid metabolism disorders from an early age.
- In adulthood, the increased risk of cardiovascular disease increases, affecting young people to a greater extent.
- In elderly patients, the progression of atherosclerosis can lead to severe complications, which requires careful monitoring of the condition.
Different age groups require an adapted approach to diagnosis and treatment.
Questions and Answers
- What are the main symptoms of homozygous familial hypercholesterolemia? The main symptoms include a significant increase in LDL levels, xanthomas on the skin and the development of atherosclerotic changes in the vessels.
- How is the disease diagnosed? Diagnosis includes cholesterol testing, genetic testing, and radiological examinations.
- Which treatment is most effective? Effective treatment includes lifestyle changes, statins, PCSK9 inhibitors, and surgery when needed.
- What are the possible complications of the disease? Potential complications include acute coronary events, strokes, and heart failure.
- What is the prognosis for treatment of homozygous familial hypercholesterolemia? With adequate treatment, the prognosis has improved, but constant monitoring and control of lipid levels is necessary.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov suggests paying attention to the following aspects when managing patients with homozygous familial hypercholesterolemia:
- Following a diet low in saturated fat can greatly improve the effectiveness of treatment.
- Regular exercise can help improve your overall health and lower your cholesterol.
- It is important to regularly monitor lipid levels in order to adjust therapy in a timely manner.
- Don't forget about the possibility of genetic counseling for family members and for early diagnosis among close relatives.
- Participation in clinical trials can provide access to the latest therapeutic approaches and drugs.
By following these recommendations, patients can significantly improve their condition and reduce the risk of cardiovascular complications.
